Trials & Filings

SunGen Pharma Receives Sixth ANDA Approval from FDA

Methylprednisolone approved for treatment of arthritis, allergic reactions, and immune system disorders

SunGen Pharma has received its sixth ANDA approval from the FDA for Methylprednisolone tablets, 4 mg.   This drug product is a corticosteroid used to treat conditions including arthritis, allergic reactions, and immune system disorders, as well as dermatologic, ophthalmic, respiratory, and gastrointestinal diseases. Methylprednisolone tablets had total U.S. sales of $93 million for 1Q19, and $113 million and $124 million, respectively, for 2018 and 2017 according to IQVIA.   “These approvals...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters